Absolute Lymphocyte Counts After Lenalidomide Initiation may Predict the Prognosis of Patients With Relapsed or Refractory Multiple Myeloma

• Published in: Cancer diagnosis & prognosis 2021-07, Vol.1 (3), p.221-229
• Main Authors: Nakagawa, Masaru, Iriyama, Noriyoshi, Ishikawa, Takuto, Miura, Katsuhiro, Uchino, Yoshihito, Takahashi, Hiromichi, Hamada, Takashi, Iizuka, Kazuhide, Koike, Takashi, Kurihara, Kazuya, Nakayama, Tomohiro, Hatta, Yoshihiro, Takei, Masami
• Format: Article
• Language: English
• ISSN: 2732-7787; 2732-7787
• DOI: 10.21873/cdp.10030

We assessed the prognosis of patients with refractory or relapsed multiple myeloma (RRMM) by focusing on the change in absolute lymphocyte counts (ALCs) after lenalidomide and dexamethasone (Ld) initiation. In total, 72 patients with RRMM were treated with Ld. ALCs were evaluated before treatment and at 1, 2, and 3 months after Ld initiation. The median ALCs in the entire cohort before and at 1, 2, 3 months after Ld initiation were 1,131, 1,059, 1,222, and 1,162/μl, respectively. ALCs before Ld initiation did not affect time to next treatment (TNT) or overall survival (OS). However, the patients with ALCs equal to or greater than the median at 3 months showed relatively better TNT than those with lower lymphocyte counts, with a significant difference. OS was also significantly longer in patients with higher ALCs. Immunomodulation by lenalidomide may improve prognosis in patients with RRMM.